Valoctocogene roxaparvovec

From WikiMD's Wellnesspedia

Valoctocogene Roxaparvovec (also known as BMN 270) is an experimental gene therapy treatment for Hemophilia A. It is being developed by BioMarin Pharmaceutical Inc.

Etymology[edit | edit source]

The name "Valoctocogene Roxaparvovec" is derived from the components of the therapy. "Valo" refers to the valine amino acid used in the therapy, "octo" refers to factor VIII, which the therapy aims to increase, "gene" refers to the gene therapy aspect of the treatment, "roxaparvo" is derived from the adeno-associated virus serotype 5 (AAV5) used as a vector in the therapy, and "vec" is short for vector.

Mechanism of Action[edit | edit source]

Valoctocogene Roxaparvovec works by delivering a functional copy of the factor VIII gene to the patient's liver cells using an AAV5 vector. This allows the liver cells to produce a continuous supply of factor VIII, which is deficient in people with Hemophilia A.

Clinical Trials[edit | edit source]

As of 2021, Valoctocogene Roxaparvovec is in Phase 3 clinical trials. The therapy has shown promise in early trials, with patients experiencing increased levels of factor VIII and decreased bleeding episodes.

Related Terms[edit | edit source]

See Also[edit | edit source]

Valoctocogene roxaparvovec Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD